Share
Micrograph of a diffuse large B cell lymphoma. Credit: Nephron / commons.wikimedia.org.

The Australian Therapeutic Goods Administration (TGA) has granted provisional approval for Specialised Therapeutics’ Minjuvi (tafasitamab) regimen for treating diffuse large B-cell lymphoma (DLBCL) in adult patients.

The regimen comprises Minjuvi plus lenalidomide followed by Minjuvi monotherapy. This treatment is indicated for usage in adult relapsed or refractory DLBCL patients who are not candidates for autologous stem cell transplant.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An immunotherapy that targets CD19, Minjuvi acts by binding to a protein on the B-cell lymphoma cell surface, inducing an immune response against the condition.

It has already received approval in the UK, Canada, the US and Europe.

The latest development was based on findings from the multicentre, single-arm, open-label Phase II L-MIND study, which assessed the safety and efficacy of Minjuvi plus lenalidomide in relapsed or refractory DLBCL patients.

See Also:

Further approval is contingent on validating and describing the regimen’s clinical benefit in the Phase III frontMIND study, which has concluded subject enrolment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Minjuvi is marketed by the company under an exclusive supply arrangement with Incyte.

Specialised Therapeutics CEO Carlo Montagner stated that securing TGA approval was a key regulatory milestone for the company.

“We are delighted to successfully register Minjuvi for Australian patients and look forward to working with the lymphoma.”

In September 2022, the Australian TGA provisionally approved Specialised Therapeutics’ Pemazyre (pemigatinib) to treat cholangiocarcinoma.